GEN Exclusives

More »

GEN News Highlights

More »
Feb 21, 2007

BG Medicine Commences Investigation for Biomarkers of Hepatotoxicity

  • BG Medicine reports that the FDA approved the first phase of the Liver Toxicity Biomarker Study (LTBS). This discovery project aims at finding biomarkers related to human hepatotoxicity in standard preclinical tests.

    It will be conducted under a CRADA with the FDA’s National Center for Toxicological Research (NCTR), as part of FDA’s Critical Path Initiative.

    The scientific advisory board will consist of seven pharmaceutical companies—Pfizer, Johnson & Johnson Pharmaceutical Research and Development, Mitsubishi Chemical Holdings, Orion, UCB, Sankyo, and Eisai—providing project funding.

    Additionally, Applied Biosystems will supply biomarker discovery systems based on mass spectrometry, including service, support, and in-kind contributions.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?